Biome Australia launches 3 new Activated Probiotic products
● Biome has successfully launched three new clinically-trialled products into its Activated Probiotics® range ● Biome Dental™, Biome Lax™ and… Read more
Nyrada Inc – Cholesterol-Lowering Program Preclinical Development Update
• Preclinical dose formulation work has been completed • Toxicology studies have been completed, safety and pharmacology studies to be… Read more
Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts
Highlights: • Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas. • First clinic will open in… Read more
Incannex Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
Highlights: • Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha… Read more
Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use
Highlights: • Incannex has engaged Catalent for the development and cGMP manufacture of Incannex’s own psilocybin drug product. • The… Read more
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
Last week, Incannex Healthcare (IHL), a biotech company at the forefront of developing novel medicinal cannabinoid compounds and psychedelic therapies,… Read more
Incannex – Independent data review commences for Phase 2 trial of psilocybinassisted psychotherapy for anxiety
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing proprietary medicinal cannabinoid products and… Read more
Incannex Expands Intellectual Property Position over IHL-42X
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and… Read more
Incannex Undertakes A$13 Million Institutional Placement; Increasing Cash to Fund Clinical Programs into 2025
Highlights: • Firm commitments received for a A$13M institutional Placement • Incannex will have a pro-forma cash position of ~A$45M… Read more